Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF10B, CS-1008(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6307MR)

This product GTTS-WQ6307MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF10B gene. The antibody can be applied in Solid tumors, research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_003842.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8795
UniProt ID O14763
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF10B, CS-1008(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6307MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6138MR IVTScrip™ mRNA-Anti-CTLA4, CP-675(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CP-675
GTTS-WQ13869MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-1979
GTTS-WQ14787MR IVTScrip™ mRNA-Anti-CD40, SGN-40(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA SGN-40
GTTS-WQ10239MR IVTScrip™ mRNA-Anti-MS4A1, LFB-R603(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA LFB-R603
GTTS-WQ6720MR IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA DS 1024
GTTS-WQ7404MR IVTScrip™ mRNA-Anti-EGFR, GA201(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GA201
GTTS-WQ11478MR IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MEHD7945A
GTTS-WQ4198MR IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BIIB019
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW